Home The Word Brain Fast Track My Amedeo FAQ About Flying Publisher   

Fast Track

Ear2MemoryFree App | Free PDF | Web
Learning languages on your smartphone
By BSK

Free Abstracts

  Lung Cancer

  Free Subscription


Articles published in Eur J Cancer

Retrieve available abstracts of 31 articles:
HTML format
Text format



Single Articles


    February 2017
  1. WALDER D, O'Brien M
    Looking back and to the future: Are we improving 'cure' in non-small cell lung cancer?
    Eur J Cancer. 2017;75:192-194.
    PubMed     Text format     Abstract available


    December 2016
  2. GEERSE OP, Hoekstra-Weebers JE, Stokroos MH, Burgerhof JG, et al
    Structural distress screening and supportive care for patients with lung cancer on systemic therapy: A randomised controlled trial.
    Eur J Cancer. 2016;72:37-45.
    PubMed     Text format     Abstract available


    November 2016
  3. YAP TA, Macklin-Doherty A, Popat S
    Continuing EGFR inhibition beyond progression in advanced non-small cell lung cancer.
    Eur J Cancer. 2016;70:12-21.
    PubMed     Text format     Abstract available


    June 2016
  4. MOLLER H, Riaz SP, Holmberg L, Jakobsen E, et al
    High lung cancer surgical procedure volume is associated with shorter length of stay and lower risks of re-admission and death: National cohort analysis in England.
    Eur J Cancer. 2016;64:32-43.
    PubMed     Text format     Abstract available


    May 2016
  5. COUREAU G, Salmi LR, Etard C, Sancho-Garnier H, et al
    Low-dose computed tomography screening for lung cancer in populations highly exposed to tobacco: A systematic methodological appraisal of published randomised controlled trials.
    Eur J Cancer. 2016 May 15. pii: S0959-8049(16)32064.
    PubMed     Text format     Abstract available


  6. MINCHOM A, Punwani R, Filshie J, Bhosle J, et al
    A randomised study comparing the effectiveness of acupuncture or morphine versus the combination for the relief of dyspnoea in patients with advanced non-small cell lung cancer and mesothelioma.
    Eur J Cancer. 2016;61:102-110.
    PubMed     Text format     Abstract available


    April 2016
  7. SHARP A, Bhosle J, Abdelraouf F, Popat S, et al
    Development of molecularly targeted agents and immunotherapies in small cell lung cancer.
    Eur J Cancer. 2016;60:26-39.
    PubMed     Text format     Abstract available


  8. YANG CY, Lin MW, Chang YL, Wu CT, et al
    Programmed cell death-ligand 1 expression is associated with a favourable immune microenvironment and better overall survival in stage I pulmonary squamous cell carcinoma.
    Eur J Cancer. 2016;57:91-103.
    PubMed     Text format     Abstract available


    March 2016
  9. WELLER A, O'Brien ME, Ahmed M, Popat S, et al
    Mechanism and non-mechanism based imaging biomarkers for assessing biological response to treatment in non-small cell lung cancer.
    Eur J Cancer. 2016;59:65-78.
    PubMed     Text format     Abstract available


  10. STEFFENS M, Paul T, Hichert V, Scholl C, et al
    Dosing to rash?--The role of erlotinib metabolic ratio from patient serum in the search of predictive biomarkers for EGFR inhibitor-mediated skin rash.
    Eur J Cancer. 2016;55:131-9.
    PubMed     Text format     Abstract available


    February 2016
  11. KARAYAMA M, Inui N, Fujisawa T, Enomoto N, et al
    Maintenance therapy with pemetrexed and bevacizumab versus pemetrexed monotherapy after induction therapy with carboplatin, pemetrexed, and bevacizumab in patients with advanced non-squamous non small cell lung cancer.
    Eur J Cancer. 2016;58:30-37.
    PubMed     Text format     Abstract available


  12. VILLARUZ LC, Socinski MA
    Is there a role of nab-paclitaxel in the treatment of advanced non-small cell lung cancer? The data suggest yes.
    Eur J Cancer. 2016;56:162-171.
    PubMed     Text format     Abstract available


    January 2016
  13. TOKITO T, Azuma K, Kawahara A, Ishii H, et al
    Predictive relevance of PD-L1 expression combined with CD8+ TIL density in stage III non-small cell lung cancer patients receiving concurrent chemoradiotherapy.
    Eur J Cancer. 2016;55:7-14.
    PubMed     Text format     Abstract available


    December 2015
  14. ABDELRAOUF F, Smit E, Hasan B, Menis J, et al
    Sunitinib (SU11248) in patients with chemo naive extensive small cell lung cancer or who have a 'chemosensitive' relapse: A single-arm phase II study (EORTC-08061).
    Eur J Cancer. 2015;54:35-39.
    PubMed     Text format     Abstract available


  15. FOURNEL P, Vergnenegre A, Robinet G, Lena H, et al
    Induction or consolidation chemotherapy for unresectable stage III non-small-cell lung cancer patients treated with concurrent chemoradiation: a randomised phase II trial GFPC - IFCT 02-01.
    Eur J Cancer. 2015;52:181-187.
    PubMed     Text format     Abstract available


  16. FITENI F, Vernerey D, Bonnetain F, Vaylet F, et al
    Prognostic value of health-related quality of life for overall survival in elderly non-small-cell lung cancer patients.
    Eur J Cancer. 2015;52:120-128.
    PubMed     Text format     Abstract available


    November 2015
  17. ROSSI M, Carioli G, Bonifazi M, Zambelli A, et al
    Trastuzumab for HER2+ metastatic breast cancer in clinical practice: Cardiotoxicity and overall survival.
    Eur J Cancer. 2015;52:41-49.
    PubMed     Text format     Abstract available


    September 2015
  18. RAKHA E, Pajares MJ, Ilie M, Pio R, et al
    Stratification of resectable lung adenocarcinoma by molecular and pathological risk estimators.
    Eur J Cancer. 2015;51:1897-903.
    PubMed     Text format     Abstract available


    August 2015
  19. HENDRIKS LE, Derks JL, Postmus PE, Damhuis RA, et al
    Single organ metastatic disease and local disease status, prognostic factors for overall survival in stage IV non-small cell lung cancer: Results from a population-based study.
    Eur J Cancer. 2015 Aug 28. pii: S0959-8049(15)00798.
    PubMed     Text format     Abstract available


  20. GIACCONE G, Bazhenova LA, Nemunaitis J, Tan M, et al
    A phase III study of belagenpumatucel-L, an allogeneic tumour cell vaccine, as maintenance therapy for non-small cell lung cancer.
    Eur J Cancer. 2015 Aug 14. pii: S0959-8049(15)00741.
    PubMed     Text format     Abstract available


  21. TOKUNAGA Y, Liu D, Nakano J, Zhang X, et al
    Potent effect of adenoviral vector expressing short hairpin RNA targeting ribonucleotide reductase large subunit M1 on cell viability and chemotherapeutic sensitivity to gemcitabine in non-small cell lung cancer cells.
    Eur J Cancer. 2015 Aug 5. pii: S0959-8049(15)00444.
    PubMed     Text format     Abstract available


  22. TAN PS, Lopes G, Acharyya S, Bilger M, et al
    Bayesian network meta-comparison of maintenance treatments for stage IIIb/IV non-small-cell lung cancer (NSCLC) patients with good performance status not progressing after first-line induction chemotherapy: Results by performance status, EGFR mutation
    Eur J Cancer. 2015 Aug 5. pii: S0959-8049(15)00664.
    PubMed     Text format     Abstract available


    July 2015
  23. YAMADA K, Aono H, Hosomi Y, Okamoto H, et al
    A prospective, multicentre phase II trial of low-dose erlotinib in non-small cell lung cancer patients with EGFR mutations pretreated with chemotherapy: Thoracic Oncology Research Group 0911.
    Eur J Cancer. 2015 Jul 11. pii: S0959-8049(15)00646.
    PubMed     Text format     Abstract available


  24. PREUSSER M, Berghoff AS, Koller R, Zielinski CC, et al
    Spectrum of gene mutations detected by next generation exome sequencing in brain metastases of lung adenocarcinoma.
    Eur J Cancer. 2015 Jul 8. pii: S0959-8049(15)00622.
    PubMed     Text format     Abstract available


  25. KOMIYA T, Madan R
    PD-L1 expression in small cell lung cancer.
    Eur J Cancer. 2015 Jul 3. pii: S0959-8049(15)00497.
    PubMed     Text format    


    June 2015
  26. O'BRIEN ME, Gaafar R, Hasan B, Menis J, et al
    Maintenance pazopanib versus placebo in Non-Small Cell Lung Cancer patients non-progressive after first line chemotherapy: A double blind randomised phase III study of the lung cancer group, EORTC 08092 (EudraCT: 2010-018566-23, NCT01208064).
    Eur J Cancer. 2015 Jun 11. pii: S0959-8049(15)00388.
    PubMed     Text format     Abstract available


  27. BLINMAN P, Hughes B, Crombie C, Christmas T, et al
    Patients' and doctors' preferences for adjuvant chemotherapy in resected non-small-cell lung cancer: What makes it worthwhile?
    Eur J Cancer. 2015 Jun 6. pii: S0959-8049(15)00454.
    PubMed     Text format     Abstract available


  28. ZHAI W, Feng R, Yang H, Wang Y, et al
    Note of clarification of data on the association between CYP2E1 RsaI polymorphism and lung cancer risk.
    Eur J Cancer. 2015 Jun 5. pii: S0959-8049(15)00453.
    PubMed     Text format    


    May 2015
  29. PLETNIKOFF PP, Laukkanen JA, Tuomainen TP, Kauhanen J, et al
    Cardiorespiratory fitness, C-reactive protein and lung cancer risk: A prospective population-based cohort study.
    Eur J Cancer. 2015 May 22. pii: S0959-8049(15)00376.
    PubMed     Text format     Abstract available


    April 2015
  30. PAWITAN Y, Yin L, Setiawan A, Auer G, et al
    Distinct effects of anti-inflammatory and anti-thrombotic drugs on cancer characteristics at diagnosis.
    Eur J Cancer. 2015;51:751-7.
    PubMed     Text format     Abstract available


    March 2015
  31. NAVARRIA P, Ascolese AM, Cozzi L, Tomatis S, et al
    Stereotactic body radiation therapy for lung metastases from soft tissue sarcoma.
    Eur J Cancer. 2015;51:668-74.
    PubMed     Text format     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Lung Cancer is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: